Last update 21 Mar 2024
FAK1 x IGF-1R x PYK2 x ALK
Focal adhesion kinase 1 x Insulin-like growth factor I receptor x Focal adhesion kinase 2 x Anaplastic lymphoma kinase
Last update 21 Mar 2024
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
评价CT-707联合特瑞普利单抗注射液和吉西他滨在晚期胰腺癌患者中的安全性、耐受性、药代动力学和有效性的Ib/II 期研究
[Translation] Phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of CT-707 in combination with toripalimab injection and gemcitabine in patients with advanced pancreatic cancer
A Phase Ib/II, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antineoplastic Activity of CT-707 in Combination With Toripalimab and Gemcitabine in Advanced Pancreatic Cancer
100 Clinical Results associated with FAK1 x IGF-1R x PYK2 x ALK
Login to view more data
100 Translational Medicine associated with FAK1 x IGF-1R x PYK2 x ALK
Login to view more data
Login to view more data
Analysis
Perform a panoramic analysis of this field.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free